Sundar Jagannath, MBBS, is a professor of medicine at the Icahn School of Medicine at Mount Sinai.
Linvoseltamab Offers Hope for Patients With Refractory Multiple Myeloma: Sundar Jagannath, MBBS
The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response rates, manageable dosing schedule, and reduced treatment burden.
Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS
Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.